that in those with established CKD, this information doesn't add to what we know
by quantifying creatinine and albuminuria. Here we discuss the evidence for urinary tubular injury markers in predicting renal outcomes in CKD and the areas where measurement of these molecules might be useful in the future.
Since chronic dialysis became widely available there has been substantial effort focused on understanding which of our patients will go on to require dialysis and/or kidney transplantation. Our duty as clinicians is to provide care founded on shared and informed decision making. This requires patients with chronic kidney disease (CKD) and their doctors to be able to access precise information about the risks of progression so as to plan for the future. This process also translates into hard clinical outcomes; for example, those who receive an adequate period of pre-dialysis preparation are more likely to start dialysis with definitive access and consequently are at lower risk of early complications and death. To this end biomarkers such as creatinine and albuminuria are established tools in helping determine who will go on to need dialysis but as a renal community, we should always be asking: Can we do this better?
The search for predictive biomarkers has also been a focus of the Acute Kidney Injury These findings seem robust: This is the largest cohort in which such an analysis has been performed. The patients included were recruited from multiple centres and with a broad range of underlying kidney diseases. Importantly methodological considerations surrounding possible biomarker degradation were controlled for.
Finally the authors demonstrate that the outcomes of their analyses were not dependent on adjustment, or not, of biomarker levels for urinary creatinine concentration. This has been a controversial issue as although it is intuitive to use creatinine to control for differences urinary concentration, urinary creatinine levels will depend not only on overall urinary concentration but also creatinine production, something that may systematically differ between study participants with stable CKD and those with progressive disease.
So what are the implications of these findings? Firstly, it is important to acknowledge that publication of what are fundamentally negative findings in high profile journal plays a crucial role in pursuit of scientific advancement. One has to wonder how many moderately sized but negative studies examining these associations never even made it to a first draft as the lead investigator considers the findings not worthy of the effort (and expense) needed to submit a manuscript. Following publication of this paper we can now say with some degree of certainty that tubular injury markers (at least KIM1, NGAL, NAG and L-FABP) aren't likely to be helpful in predicting renal outcomes in a typical clinic population with CKD.
Of course we should also ask what help from biomarkers are we are looking for? As the authors allude to when faced with a patient with established CKD in clinic we are already have pretty good tools to identify those who will progress to the need for dialysis. We routinely quantify eGFR and albuminuria which, unlike risk factors for atherosclerotic cardiac events such as hyperlipidaemia that predict occurrence of new disease, are markers of established pathology and/or physiological compensation and therefore provide a window onto the disease itself. Furthermore, if we add change in eGFR over time to our decision-making (something which the authors of this report did not do) we can increase our ability to determine who will progress to dialysis even further. 7 Of course there remains a degree of uncertainty, and given the interplay between AKI and CKD one wonders whether this is explained by episodes of the former. The implication being that much of this uncertainty as to renal prognosis might not be possible to capture using biomarkers. After all, future information on the events that lead to AKI, e.g. the prescription of a nephrotoxic medication or the timing of the acquiring a bacterial pneumonia are unlikely to be obtainable from urine. 
